Oral small molecule GLP-1 receptor agonists represent a significant shift in metabolic pharmacology. Where peptide analogs like Semaglutide and Liraglutide are large, acylated peptides that must be injected subcutaneously, small molecules such as Orforglipron (LY3502970) and Danuglipron are orally bioavailable compounds that fit entirely within the transmembrane binding pocket of GLP-1R. They activate the same […]
Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition worldwide, affecting approximately one in four adults globally. For most people it remains stable, but in 20-30% of cases it progresses to non-alcoholic steatohepatitis (NASH) a state of active inflammation and hepatocellular injury that can advance to fibrosis, cirrhosis, and hepatocellular carcinoma. Understanding where […]
Semaglutide (Ozempic, Wegovy, Rybelsus) is the most widely prescribed GLP-1 receptor agonist, and one of the most studied pharmacological agents in metabolic disease research. Its effects extend well beyond glycaemic control encompassing appetite regulation, adipose tissue biology, hepatic function, cardiovascular risk markers, and inflammatory mediators. For researchers conducting mechanistic studies, pharmacodynamic assessments, or comparing Semaglutide […]
Checkpoint blockade therapy is not limited by the absence of immune cells alone — it is limited by the architecture, metabolic state, and regulatory circuitry of the tumor microenvironment (TME). Response to PD-1/PD-L1 or CTLA-4 inhibition requires a pre-existing, tumor-specific T cell response that is restrained rather than absent. Failure occurs when antigen presentation is […]
Explore Krishgen’s blog for expert insights on ELISA assays, life science research, biotech innovations, laboratory best practices, and product updates designed to support scientists and research institutions.
